Figure 7.
Survival curves showing therapeutic efficacy of C2-2b-2b in disseminated Burkitt lymphoma (Daudi) and multiple myeloma (CAG) xenograft models. Female CB17 SCID mice were inoculated with CAG (A) or Daudi (B-C) cells intravenously on day 0. Treatment was administered as a single subcutaneous dose on day 7. Survival curves were analyzed with Prism software. (A-B) Dose-escalation study. Groups of 10 mice were treated with C2-2b-2b at 1 μg, 10 μg, 30 μg, or 60 μg. (C) Efficacy compared with hL243 and IFNα. Groups of 12 or 13 mice were given a single dose of C2-2b-2b (1 μg, 4pmol, 15 500 IU), 734-2b-2b (1 μg, 4pmol, 15 500 IU), 0.6 μg (4pmol) hL243 IgG1, + 15 500 IU rIFNα2b or peginterferonalfa-2a [1 μg, 16pmol, and 5 μg, 80pmol).